Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

Background/AimsDecreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could become...

Full description

Bibliographic Details
Main Authors: Akihiro Koga, Toshiyuki Matsui, Noritaka Takatsu, Yasumichi Takada, Masahiro Kishi, Yutaka Yano, Takahiro Beppu, Yoichiro Ono, Kazeo Ninomiya, Fumihito Hirai, Takashi Nagahama, Takashi Hisabe, Yasuhiro Takaki, Kenshi Yao, Hirotsugu Imaeda, Akira Andoh
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2018-04-01
Series:Intestinal Research
Subjects:
Crohn disease
Infliximab trough level
Mucosal healing
Loss of response
Antibodies to infliximab
Online Access:http://www.irjournal.org/upload/pdf/ir-16-223.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-16-223.pdf

Similar Items